Roche’s Crenezumab Creeps Forward But Has All To Play For In Phase III Trials

Phase II data for Roche’s Alzheimer’s disease MAb, crenezumab, has upheld its proposed mechanism of action but competitor aducanumab still has the upper hand with evidence of disease-modifying potential.

Elderly woman hands holding missing white jigsaw puzzle piece down into the place as a human head brain shape. Creative idea for memory loss, dementia, Alzheimer's disease and mental health concept.

Crenezumab, Roche’s Alzheimer’s disease (AD) candidate, has been shown to significantly reduce amyloid beta (A-beta) oligomers in cerebrospinal fluid (CSF) in patients in Phase II trials, supporting the proposed mechanism of action for the drug and moving it along the road to commercialization in a therapy area that has seen a lot fall by the wayside. However, the candidate has some significant ground to make up when compared with Biogen Inc.’s aducanumab.

Crenezumab is a fully humanized IgG4 monoclonal antibody that binds all forms of misfolded A-beta proteins, but especially to A-beta...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D